Streetbeat News

Products Services

DNB

PRLB

Stacy Greiner, COO of DailyPay, will be participating in Benzinga's Fintech Deal Day event. Greiner has a diverse background in engineering, product development, marketing and management, and has held senior roles at Cisco, IBM, Accenture, and Dun & Bradstreet Holdings Inc. She is also a board member of Proto Labs, Inc. DailyPay is an on-demand B2B payment solution that allows users to access their earned income immediately.

Portfolio Pulse from Stjepan Kalinic

October 23, 2023 | 3:27 pm

APLM

Apollomics has announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at ESMO 2023, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 3:11 pm

AXP

Charles O’Neill, a senior manager of Emerging Partnerships at AmEx Digital Labs, is a key figure in American Express's (NYSE:AXP) venture into Web 3. The AmEx Digital Labs division, formed in 2017, focuses on developing and testing new technologies. O’Neill has been working with Proof of attendance protocol (POAP), an Ethereum-based protocol, to create digital impressions preserved on the blockchain. By partnering with POAP, AmEx users can claim NFTs minted directly to their approved Web3 wallets.

Portfolio Pulse from Stjepan Kalinic

October 23, 2023 | 2:57 pm

AZN

AstraZeneca and Daiichi Sankyo's ENHERTU demonstrated clinically meaningful survival in the DESTINY-PanTumor02 Phase II trial for patients with HER2-expressing advanced solid tumors. The trial showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months. The results support ongoing discussions with global regulatory authorities and reaffirm the potential role of ENHERTU as a tumor-agnostic therapy.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:56 pm

ALKS

Alkermes plc (NASDAQ:ALKS) has announced preliminary results from a phase 1 study evaluating ALKS 2680, a novel orexin 2 receptor agonist in development for the treatment of narcolepsy. The data demonstrated dose-dependent, significantly improved sleep latency compared to placebo in Narcolepsy Type 1. The drug was generally well tolerated at all doses tested. The company plans to initiate a phase 2 study of ALKS 2680 in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:45 pm

NVS

Novartis AG's Pluvicto has shown statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in pre-taxane setting. The Phase III PSMAfore trial with Pluvicto met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411. Pluvicto also showed improved quality of life compared to daily oral ARPI, along with improvements in other clinically meaningful efficacy endpoints. Novartis is investigating a broad portfolio of RLTs in advanced cancers and is investing in production capacity to meet global patient needs.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:38 pm

NOTE

VGK

FiscalNote Holdings, Inc. (NYSE:NOTE) has announced enhancements to its European Union Issue Tracker (EUIT), expanding stakeholder coverage and providing AI-powered transcripts of all European Parliament committee meetings. The enhancements will allow customers to track all 705 active Members of the European Parliament (MEPs), access up-to-date information on the issues lawmakers are working on, and receive AI-generated committee transcripts within a few hours. The company aims to equip decision makers with immediate and crucial information to respond to emerging issues and risks.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:33 pm

BOLT

Bolt Biotherapeutics (NASDAQ:BOLT) has presented updated data from its Phase 1 dose-escalation trial of BDC-1001 at the ESMO 2023 Congress. The data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose. BDC-1001 is an investigational Immune-Stimulating Antibody Conjugate (ISAC) in development for the treatment of patients with HER2-positive cancer. The company plans to initiate Phase 2 dose-expansion clinical trial in patients with HER2-positive colorectal, breast, endometrial and gastric cancers.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:32 pm

AZN

AstraZeneca and Daiichi Sankyo's drug, datopotamab deruxtecan, has shown positive results in the TROPION-Breast01 Phase III trial, reducing the risk of disease progression or death by 37% in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer. The drug also demonstrated a favorable safety profile over chemotherapy. The companies plan to continue discussions with regulatory authorities to bring the drug to eligible patients as soon as possible.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:31 pm

OLIT

Syntec Optics, a provider of scientific and technical instruments and aerospace and defense optics, is set to list on Nasdaq via a merger with OmniLit. The company has been a pioneer in the manufacturing of scalable ultra-high precision optics for Low Earth Orbit (LEO) satellite systems. Syntec Optics is well-positioned to provide ultra-precision optics to enable the expanding market for satellites, which is projected by Morgan Stanley to reach $1 trillion by 2040.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:05 pm